

## 9. Literaturverzeichnis

1. AWMF-Leitlinien: PSA Bestimmung in der Prostatakarzinomdiagnostik, September 2002, <http://www.leitlinien.net>
2. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, et al: *Prostate Cancer Mortality after Introduction of Prostate-Specific Antigen Mass Screening in the Federal State of Tyrol, Austria*. Urology 2001; 58:417-424.
3. Becker N: *PSA-Test zur Früherkennung des Prostatakarzinoms*. Der Onkologe 2004;10:66-74.
4. Benoit RM, Naslund MJ, Cohen JK: *Complications after radical retropubic prostatectomy in the medicare population*. Urology 2000;56:116-120.
5. Berger AP, Deibl M, Steiner J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W: *Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk*. Prostate 2005 Aug 1; 64(3):240-5.
6. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson S-O, et al.: *Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer*. N Engl J Med 2005 ; 352:1977-1984.
7. Candas B, Cusan L, Gomez J-L, Diamond P, Suburu RE, et al.: *Evaluation of Prostatic Specific Antigen and Digital Rectal Examination as Screening Test for Prostate Cancer*. Prostate 2000; 45:19-35.
8. Catalona WJ, Hudson MA, Scardino PT, et al.: *Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristics curves*. J Urol 1994;152:2037-2042.
9. Catalona WJ, Ramos CG, Carvalhal GF, Yan Yan: *Lowering PSA cutoffs to enhance detection of curable prostate cancer*. Urology 2000; 55:791-795.
10. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, et al: *Measurement of Prostate-Specific Antigen in Serum as Screening Test for Prostate Cancer*. N Engl J Med 1991; 324: 1156-1161.
11. Cheli CD, Levine RL, Cambetas DR, Kolker JD, Roberts SB: *Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign*. Urology 2002;60(Suppl1):53-9.
12. Coldman AJ, Phillips N, Pickles TA: *Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity*. CMAJ 2003; 168:31-35.

13. Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, et al.: *The Effectiveness of Screening for Prostate Cancer-A Nested Case-Control Study*. Arch Intern Med.2006;166:38-43.
14. Dalkin BL, Ahmann FR, Kopp JB: *Prostate specific antigen levels in men older than 50 years without clinical evidence for prostatic cancer*. J Urol 1993;150: 1837-9.
15. Dawson B, Trapp RG: *Basic and Clinical Biostatistics*. Lange medical books, third edition, 2001.
16. Deutsche Gesellschaft für Urologie e.V., Berufsverband der Deutschen Urologen e.V.: *Promis gegen Prostatakrebs – Früherkennung rettet Leben*. Ausgabe 1/2006.
17. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F: *Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult*. BMJ. 2002 Oct 5;325(7367):766-70.
18. Draisma G, Boer R, Otto SJ, van der Crujisen IW, Damhuis RAM, Schröder FH, de Koning HJ: *Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer*. Journal of National Cancer Institute 2003; Vol.95, No.12: 868-878.
19. Efstathiou JA, Chen Ming-Hui, Catalona WJ, McLeod DG, Carroll PR, et al.: *Prostate-Specific Antigen-Based Screening May Decrease Prostate Cancer-Specific Mortality*. Urology 2006;68:342-347.
20. Epstein JI, Walsh PC, Carmichael M, Brendler CB: *Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer*. JAMA 1994;271(5),368-74.
21. Fornara P: *PSA-Test – Stimmungsmache*. Dt Ärzteblatt 2003; 42: A-2703.
22. Frankel S, Smith GD, Donovan J, Neal D: *Screening for prostate cancer*. Lancet 2003; 361:1122-1128.
23. Freedland SJ, Mangold LA, Walsh PC, Partin AW : *The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy*. The Journal of Urology 2005;174:1276-1281.
24. Frohmüller H, Theiß M, Bracher F: *Prostatakarzinom*. Prostataerkrankungen im höheren Lebensalter; Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 2002:159-210.
25. Gaus W: *Ist Screening auf Prostatakarzinom nützlich? Biometrische Beurteilung der Studie: 1988 Quebec Prospective Randomized Controlled Trial*. Persönliche Mitteilung, 2006.

26. Goepel M, Schulze H, Sökeland J: *Die benigne Prostatahyperplasie – Pathogenese, Diagnostik und konservative Therapie*. Dt Ärzteblatt 2000; 97:A1677-1681 [Heft 24].
27. Gohagan JK, Prorok PC, Hayes RB, Kramer BS: *The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status*. Control Clin Trials 2000; 21:251S-272S.
28. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, et al.: *Cancer Surveillance Series: Interpreting Trends in Prostate Cancer-Part I: Evidence of the Effects of Screening in Recent Prostate Cancer Incidence, Mortality, and Survival Rates*. Journal of the National Cancer Institute 1999; Vol. 91: 1017-1024.
29. Hanks G E, Scardino P T: *A comparison of prostate cancer treatments: are therapeutic implications justified?* Cancer J Sci Am 1997;30(2):70-2.
30. Johansson J-E, Andrén O, Andersson S-O, Dickman PW, et al. : *Natural History of Early, Localized Prostate Cancer*. JAMA 2004; 291:2713-2719.
31. Jung K, Lein M, Butz H, Stephan C, Loening SA, Keller T: *New Insights Into the Diagnostic Accuracy of Complexed and Total Prostate Specific Antigen Using Discordance Analysis Characteristics*. The Journal of Urology 2006;175:1275-1280.
32. Koch K: *PSA-Test und Prostatakarzinom-Ein Beispiel für das Dilemma der Früherkennung*. Dt Ärzteblatt 2003; 39: A-2486-2488.
33. Köhler A, Gibis B, Mühlich A: *Mammographie Screening – Flächendeckendes Angebot bereits im Jahr 2005*. Dt Ärzteblatt 2003; 100: A-1240-1243[Heft 19].
34. Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N: *Screening with Prostate Specific Antigen and Metastatic Prostate Cancer Risk: A Population Based Case-Control Study*. J Urol 2005;174:495-499.
35. Krahn MD, Coombs BA, Levy IG: *Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen*. CMAJ 1999;160:49-57.
36. Krebsregister Saarland: <http://www.krebsregister.saarland.de>
37. Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al.: *Screening Decreases Prostate Cancer Mortality: 11-Year Follow-Up of the 1988 Quebec Prospective Randomized Controlled Trial*. The Prostate 2004; 59:311-318.
38. Loertzer H, Fischer K, Fornara P: *PSA quick test in capillary blood*. Anticancer Res. 2005 May-Jun;25(3A):1659-62.
39. Luboldt HJ, Swoboda A, Husing J, Rubben H, et a.: *Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0ng/ml prostate-specific antigen as cutoff*. EurUrol.2001 Feb;39(2):131-7.

40. Moul JW, Sun L L, Hotaling J, Scales CD, Pappas P, et al.: *Age-adjusted PSAV and prostate cancer screening*. ASCO Prostate Cancer Symposium, San Francisco 24.-26.02.2006 Abstract.
41. Oesterling JE, Jacobsen SJ, Chute CG, et al.: *Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges*. JAMA 1993;270:860-4.
42. Paquette EL, Sun L, Paquette LR, Conelly R, Mcleod DG, Moul JW: *Improved Prostate Cancer-specific Survival and other Disease Parameters: Impact of Prostate Specific Antigen Testing*. Urology 2002;60:756-769.
43. Robert Koch Institut : <http://www.rki.de>
44. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, et al: *Age and Racial Distribution of Prostatic Intraepithelial Neoplasia*. Eur Urol 1996;30:138-144.
45. Scheffer S, Dauven S, Sieverding M: *Soziodemografische Unterschiede in der Teilnahme an Krebsfrüherkennungsuntersuchungen (KFU) in Deutschland – Eine Übersicht*. Gesundheitswesen 2006; 68: 139-146.
46. Schmid HP, Altwein JE, Faul P, Wirth M: *Screening und Früherkennung des Prostatakarzinoms-Zwischen Szylla und Charybdis*. Dt Ärztebl 1999;96:A-772-777 [Heft 12].
47. Schmid HP, Stamey TA, McNeal JE, Freiha FS, Redwine EA, Whittemore AS: *Einfluß der natürlichen Geschichte auf die Handhabung des Adenokarzinoms der Prostata*. Urologe [A] 1994; 33:144-148.
48. Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ: *4-Year Prostate Specific Antigen Progression and Diagnosis of Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam*. The Journal of Urology 2005; 174: 489-494.
49. SEER Incidence and U.S. Death Rates, Prostate Cancer; National Cancer Institute, <http://www.seer.cancer.gov>
50. Semjonow A, De Angelis G, Oberpenning F et al. (2000): *The clinical impact of different assays for prostate specific antigen*. BJU Int 86(5): 590–597.
51. Siesling S, van Dijck JAAM, Visser O, Coebergh JWW: *Trends in incidence and mortality from cancer in The Netherlands in the period 1989-1998*. European Journal of Cancer 2003; 39:2521-2530.
52. Sieverding M: *Achtung! Die männliche Rolle gefährdet Ihre Gesundheit!* Psychomed 16/1, 25-30 (2004).
53. Sieverding M: Persönliche Mitteilung August 2006.

54. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J: *The Prostate Specific Antigen Era in the United States is over for Prostate Cancer: What Happened in the Last 20 Years?* The Journal of Urology 2004; Vol.172: 1297-1301.
55. Statistisches Bundesamt, *Statistisches Jahrbuch 2005*. <http://www.destatis.de>
56. Statistisches Bundesamt: Gesundheitsbericht für Deutschland, 1998 <http://www.gbe-bund.de>
57. Stenzel A, Anastasiadis A, Belka C, Bichler H, Bokemyer C, Cuno P, et al.: *Prostatakarzinom Therapieempfehlungen*. Interdisziplinäres Tumorzentrum am Klinikum der Eberhard-Karls-Universität Tübingen 2004;1.Auflage 01/04.
58. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al.: *Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level less than/equal 4.0 ng per Milliliter*. N Engl J Med 2004; 350: 2239-2246.
59. Veltri RW, Miller MC, O'Dowd GJ, Partin AW: *Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer*. Urology 2002;60(Suppl4A):47-52.
60. Vutuc C, Haidinger G: *Qualitätsstandards beim Screening*. Österreichische Vereinigung für klinische Onkologie, Krebs:hilfe! 2004; 4:35-36.
61. Weinmann S, Richert-Boe KE, Van Den Eeden SK, Enger SM, Rybicki BA, et al.: *Screening by Prostate-Specific Antigen and Digital Rectal Examination in Relation to Prostate Cancer Mortality – A Case-Control Study*. Epidemiology 2005;16:367-376.
62. Weißbach L, Boedefeld E A: *Diagnose: Prostatakrebs Ein Ratgeber-nicht nur für Männer*; Zuckschwerdt Verlag 2005:41.
63. Weymayr C, Koch K: *Prostatakrebs*. Mythos Krebsvorsorge-Schaden und Nutzen der Krebsfrüherkennung; Eichborn AG 2003:141-171.
64. Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland: <http://www.zi-berlin.de> .